[Consensus statement of the migraine and headache societies (DMKG, ÖKSG, and SKG) on the duration of pharmacological migraine prophylaxis].
Options
BORIS DOI
Date of Publication
April 2023
Publication Type
Article
Division/Institute
Author
Goßrau, Gudrun | |
Förderreuther, Stefanie | |
Ruscheweyh, Ruth | |
Ruschil, Victoria | |
Sprenger, Till | |
Lewis, David | |
Kamm, Katharina | |
Freilinger, Tobias | |
Neeb, Lars | |
Malzacher, Volker | |
Meier, Uwe | |
Gehring, Klaus | |
Kraya, Torsten | |
Dresler, Thomas | |
Gantenbein, Andreas R | |
Brössner, Gregor | |
Zebenholzer, Karin | |
Diener, Hans-Christoph | |
Gaul, Charly | |
Jürgens, Tim P |
Subject(s)
Series
Der Nervenarzt
ISSN or ISBN (if monograph)
1433-0407
Publisher
Springer
Language
German
Publisher DOI
PubMed ID
36287216
Uncontrolled Keywords
Description
Migraine is the most common neurological disorder and can be associated with a high degree of disability. In addition to non-pharmacological approaches to reduce migraine frequency, pharmacological migraine preventatives are available. Evidence-based guidelines from the German Migraine and Headache Society (DMKG), and German Society for Neurology (DGN), Austrian Headache Society (ÖKSG), and Swiss Headache Society (SKG) are available for indication and application. For therapy-relevant questions such as the duration of a pharmacological migraine prevention, no conclusions can be drawn from currently available study data. The aim of this review is to present a therapy consensus statement that integrates the current data situation and, where data are lacking, expert opinions. The resulting current recommendations on the duration of therapy for pharmacological migraine prophylaxis are shown here.